Multiple Myeloma
2,314
334
532
1,064
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
534 trials with published results (23%)
Research Maturity
1064 completed trials (46% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
12.8%
296 terminated out of 2314 trials
78.2%
-8.3% vs benchmark
12%
272 trials in Phase 3/4
50%
534 of 1064 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1064 completed trials
Clinical Trials (2314)
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
Pre-malignant States to Hematologic Malignancies in Firefighters
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study